At week 12 , the PASI 75 response rates were higher with brodalumab at the 210-mg and 140-mg doses than with placebo ( 86 % and 67 % , respectively , vs. 8 % [ AMAGINE-2 ] and 85 % and 69 % , respectively , vs. 6 % [ AMAGINE-3 ] ; P < 0.001 ) ; the rates of sPGA scores of 0 or 1 were also higher with brodalumab ( P < 0.001 ) .